VCEL Q4 2025 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93M+23.3% YoY

Gross Profit

$73M78.7% margin

Operating Income

$22M24.1% margin

Net Income

$23M25.0% margin

EPS (Diluted)

$0.45

QoQ Revenue Growth

+37.7%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$802,000

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$488M

Total Liabilities

$133M

Stockholders' Equity

$355M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$75M	+23.3%
Gross Profit	$73M	$58M	+25.0%
Operating Income	$22M	$18M	+21.3%
Net Income	$23M	$20M	+17.3%

Revenue Segments

MACI Implants And Kits

$84M100%